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DOI 10.1186/s12955-015-0308-3RESEARCH ARTICLE Open AccessPatterns of health-related quality of life and
associated factors in Chinese patients
undergoing haemodialysis
Eric Y. F. Wan1, Julie Y. Chen1,2*, Edmond P. H. Choi3, Carlos K. H. Wong1, Anca K. C. Chan1, Karina H. Y. Chan1
and Cindy L. K. Lam1Abstract
Background: Haemodialysis (HD) is a life-saving but burdensome therapy for patients with end-stage renal disease
(ESRD) which can have a detrimental impact on patients’ quality of life and outcomes. There is currently little data
on the health related quality of life (HRQOL) of Chinese ESRD patients undergoing HD and this study sought to
examine the patterns of HRQOL and its associated factors within this population, as well as in comparison with the
general local population.
Methods: A cross-sectional study of 244 ESRD patients receiving HD in the hospital and in the community in Hong
Kong was conducted using the Short Form-12 Health Survey version 2 (SF-12v2). All study subjects were one-to-one
matched with subjects in a Hong Kong general population database by sex and exact age. Independent t-tests were
performed to compare the mean SF-12v2 scores between HD patients and the general population, followed by
one-way analysis of variance with post hoc Tukey’s HSD tests to compare community-based haemodialysis,
hospital-based haemodialysis and the general population. Multiple linear regressions were used to identify the
factors (socio-demographic, clinical characteristics and comorbidities) associated with the HRQOL scores of ESRD
patients receiving HD.
Results: The SF-12v2 Physical Functioning, Role Physical, Bodily Pain, General Health and Physical Component
Summary scores of HD patients were significantly lower than the age-sex adjusted general population. However, the
SF-12v2 Mental Health and Mental Component Summary scores of HD patients were significantly higher than the
corresponding general population. Poorer HRQOL was associated with being female, smoking, unemployment and
hospital-based haemodialysis.
Conclusions: HD patients had substantially poorer physical HRQOL but better mental HRQOL than the age-sex
adjusted general population. Patients receiving HD in the community setting had better HRQOL. Reasons for these
observations will need to be further investigated. Those patients who are female, smokers and unemployed may
warrant more attention as their poorer HRQOL may be associated with poorer outcomes.
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Chronic kidney disease (CKD) is an emerging global
health problem. According to the Global Burden of
Disease Study in 2010, chronic kidney disease rose from
27th in 1990 to 18th in 2010, in the list of causes of total
number of global deaths [1]. CKD is a significant prob-
lem in Asia [2] with a prevalence of 11.9 % in Taiwan [3]
and 10.8 % in Mainland China [4]. This is due to the in-
creasing prevalence of key causes of CKD, hypertension
and diabetes mellitus, which in turn increase the health
burden attributable to CKD in the future [5].
Due to the progressive nature of CKD, many patients
with CKD are likely to deteriorate to end-stage renal dis-
ease (ESRD) and eventually require some form of renal
replacement therapy such as renal transplant, haemodi-
alysis (HD) or peritoneal dialysis (PD). HD is the most
effective mode of renal replacement therapy after renal
transplantation, but is expensive and burdensome to the
patient. In Asia, over 90 % of dialysis patients were on
HD in China and Taiwan in 2005-2006 [6, 7] which
contrasts sharply with the situation in Hong Kong where
PD is designated as first-line therapy according to gov-
ernment policy. HD is reserved for those in whom PD
has failed or who have medical contraindications to-
wards PD [8, 9]. This accounts for the comparatively low
percentage of HD patients in Hong Kong compared with
the rest of the developed world. According to the most
recent Hong Kong Renal Registry Report 2012, 1,246
(15.2 %) of patients in Hong Kong who needed renal
replacement therapy were undergoing HD with the re-
mainder on PD (43.6 %) or with a functioning renal
transplant (40.3 %) [10]. Of the HD patients, over 60 %
were treated in government-funded hospital-based renal
units [10].
Though a life-saving therapy, HD can have a signifi-
cant negative impact on the quality of patients’ lives. On
a day-to-day basis, the frequency of dialysis and long
duration of dialysis sessions limits patients’ independent
living [11]. From a longer term perspective, HD can result
in increased dependence on caregivers, loss of freedom,
disturbance to family and to social life [12]. This, coupled
with a stringent diet and fluid restriction, and the symp-
toms associated with ESRD itself, may be detrimental to
overall health-related quality of life (HRQOL) [13–17].
HRQOL is an important health outcome for studies
evaluating the impact of illness, clinical trials, audits of
the quality of healthcare and analyses of cost-effectiveness
[18, 19]. Furthermore, it has shown to be a clinically
important dialysis outcome [20]. The majority of the pub-
lished studies about the impact of HRQOL for ESRD pa-
tients receiving HD have been conducted in non-Chinese
populations [13–17, 21]. However, HRQOL is a culture-
specific construct as shown by the variation in relationship
between HRQOL and outcomes such as patient survival,compliance and the patterns of medical practice [22–25]
among international populations of ESRD patients. Aware-
ness of culturally specific HRQOL issues in Chinese HD
patients could facilitate a more patient-centred approach
to health care.
However the comparison of HRQOL between HD pa-
tients in Hong Kong and HD patients may be affected
by the aforementioned ‘PD first policy’ in Hong Kong.
Patients undergoing HD in Hong Kong are likely to be
more ill and to have poorer health status in contrast to
the baseline state of HD patients in other countries
where HD is the first choice for treatment of patients
with ESRD and patients may be relatively healthier.
Understanding the impact of HRQOL of community-
based and hospital-based HD patients with ESRD can
provide a more comprehensive evaluation of quality of
care than traditional clinical parameters alone. Know-
ledge of the difference in HRQOL between HD patients
with ESRD and the general population can provide valu-
able insight on the physical and psychosocial burden of
chronic illness and its treatment. Hence, the aim of this
study was to evaluate the HRQOL of Chinese patients
with ESRD undergoing HD. The specific objectives of
the study were: (1) to compare HRQOL of community-
based and hospital-based HD patients, (2) to compare
HRQOL of HD patients with that of the Hong Kong
general population; and (3) to identify the risk factors
for poorer HRQOL in Chinese patients with HD.
Methods
This was a cross-sectional observational study. Subjects
were recruited from two different settings to include
patients with a broad spectrum of characteristics. The
subject recruitment period was from October 2012 to
March 2013:
The community-based haemodialysis (CBHD) setting,
for this study was the Haemodialysis Public Private Part-
nership (HD-PPP), a shared-care programme that gives
eligible patients the option of receiving HD treatment in
the community while continuing to be followed up in
the renal clinic of the public hospital. Participants were
predominantly PD patients who converted to HD for
medical reasons (i.e. poor ultrafiltration, inadequate dia-
lysis or frequent bacterial/fungal peritonitis on PD), who
had good vascular access, were haemodynamically stable,
and were mentally sound, ambulatory and independent
for HD and who wished to join the CBHD programme.
In this service provision model, HD services are pur-
chased from non-government HD providers in the com-
munity without additional cost to the patient. In order
to maintain the quality of care of the HD service, the
protocols for HD were standardized across different
community centres. During the study period, there were
five community-based HD centres which provided HD
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All 124 HD-PPP patients were invited to join this study.
In a government-funded hospital-based HD (HBHD)
setting, patients who were undergoing HD in thirteen
government-funded hospitals across Hong Kong were
recruited by convenience sampling. Eligible patients
were invited by trained research assistants to take part
in this study.
All subjects in community-based HD centres of the
HD-PPP programme were recruited to join the study
whilst patients in government-funded hospital-based HD
Units were recruited by convenience sampling until a
target sample size was reached. Subjects from both set-
tings were excluded if they were aged < 18 years; could
not understand Cantonese; had cognitive impairment,
refused to participate; or were too ill to give consent
(i.e. patients who reported they were too fatigued to
complete the questionnaire or patients who were in
isolation due to illness). Trained research assistants ex-
plained the nature of the study and invited subjects to
participate. Those patients who agreed to participate and
who provided written consent then completed a struc-
tured interviewer-administered questionnaire.
In order to compare the HRQOL of our study subjects
against the Hong Kong general population, we identified a
matching subject from the Hong Kong population study
dataset for each subject in our study. This was possible be-
cause we had access to the original data set of the Chinese
(Hong Kong) SF-12 Health Survey-Version 2 Hong Kong
population study [26] (previously conducted by one of our
co-authors), which surveyed 2533 subjects by random
sampling. A match was defined as subjects of the same
gender and exact age in year. This was done in accordance
with well-accepted methodology to match for age and
gender when comparing HRQOL to population norms.
Age and gender were selected as matching criteria as they
are strong factors affecting HRQOL whose effect must be
controlled for when comparing to the general population.
Previous studies also adopted this methodology to com-
pare the HRQOL of patient populations against the gen-
eral population [27, 28].
Ethics approval
Ethics approval of this study was granted by all local
Institutional Review Board (HKU/HA HKW: UW 10-366;
HKEC: HKEC-2010-096; KEC/KCC: KC/KE-10-0208/
ER-3; KWC: KW/EX/10-150 (34-17); CUHK/NTEC:
CRE-2011.051); NTWC: NTWC/CREC/911/11). Infor-
med consent was obtained from all patients.
Outcome
The primary outcome in this study was HRQOL as mea-
sured by the Chinese (Hong Kong) Short Form-12
Health Survey version 2 (SF-12v2).Study instruments
The Chinese (Hong Kong) SF-12 Health Survey-Version 2
(SF-12v2)
The SF-12 v2 has been validated and normed on the gen-
eral Chinese adult population in Hong Kong [26, 29]. It
measures eight domains of HRQOL on Physical Function-
ing (PF), Role Physical (RP), Bodily Pain (BP), General
Health (GH), Vitality (VT), Social Functioning (SF), Role
Emotional (RE) and Mental Health (MH) on a scale with
theoretical range from 0 to 100. A higher score indicates
better HRQOL. The eight domain scores can be aggre-
gated based on population-specific weights to calculate
two summary scores, the Physical (PCS) and Mental
Component Summary (MCS) scores.
Socio-demographic, clinical and comorbidity information
Demographic data including gender, age, marital status,
educational level, smoking habit, and employment status
were collected by a structured questionnaire. Clinical out-
come measures such as dialysis efficacy as calculated by
Kt/V and haemoglobin were extracted from medical re-
cords. The target value of Kt/V was defined as Kt/V ≥ 1.8
for patients receiving 2 HD sessions per week, or Kt/
V ≥ 1.2 for patients receiving 3 HD sessions per week, or
Kt/V ≥ 3.6 for weekly data [30]. The target haemoglobin
was 9 g/dL or greater. Presence of co-morbidity was de-
fined as having any of the following conditions: diabetes
mellitus, hypertension, cancer, acute myocardial infarc-
tion, other chronic ischemic heart disease, congestive
heart disease, stroke, peripheral vascular disease and
chronic lung disease.
Data analysis
Descriptive statistics were used to describe the cha-
racteristics and summarize the SF-12v2 scores of the
subjects. Differences in baseline characteristics between
CBHD and HBHD patients were tested by independent
t-tests for continuous variables or chi-square tests for
categorical variables. All HD patients were one-to-one
matched with the Hong Kong general population by sex
and exact age and independent t-tests were used to as-
sess the differences in mean SF-12v2 scores [26]. Such
comparisons of HRQOL scores were similarly performed
in previous studies [27, 28]. The Cohen’s d effect sizes
were also calculated and the value was interpreted as triv-
ial for < 0.2, small for ≥ 0.2 and < 0.5, moderate for ≥ 0.5
and < 0.8 or large for ≥ 0.8 [31]. The differences in mean
SF-12v2 scores across two settings and Hong Kong gen-
eral population were further analyzed by one-way analysis
of variance (ANOVA) with post hoc Tukey’s HSD test if
there were significant differences between the three
groups. The internal consistency of the SF-12v2 domain
scores was assessed by Cronbach’s alpha coefficient, with a
value ≥ 0.7 indicating adequate internal consistency [32].
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ics, clinical and comorbidity information) and HRQOL
were assessed by multiple linear regressions.
All statistical analysis was performed using STATA
Version 13.0 (StataCorp LP, College Station, Tex). All sig-
nificance tests were two-tailed and findings with a p-value
less than 0.05 were considered statistically significant.Results
Subjects
A total of 305 eligible subjects (124 CBHD patients; 181
HBHD patients) were approached in five community-
based HD centres and thirteen government-funded
hospital-based HD Units. Amongst all, 244 patients con-
sented to participate which gave a response rate of 80 %
of all eligible patients approached. 110 (88.7 %) of 124
HD-PPP programme patients who were receiving HD in
community-based centers completed the face-to-face
interview. 134 (74.0 %) of 181 subjects who were receiv-
ing HD in government-funded hospital-based HD cen-
ters completed the face-to-face interviews.
The socio-demographic and clinical characteristics of
CBHD and HBHD patients are displayed in Table 1.
There were no statistical differences in socio-demographics
except employment status and transportation means. More
patients in HBHD were in active employment and travelled
by taxi to their HD service. There was no significant differ-
ence between the two groups in dialysis adequacy (Kt/V)
or hemoglobin level, two conventional clinical outcome
measures. Moreover, both groups had similar proportions
of patients suffering from co-morbidities.Health-related Quality of Life of Patients with HD
Table 2 presents the means and the standard deviations
(SD) of HRQOL scores. Out of 2,831 subjects in the sex-
age adjusted general population in Hong Kong, 233 were
one-to-one matched with the HD patients under study
by both sex and exact age and their SF-12v2 scores were
compared. 11 out of 244 subjects could not be matched.
Overall, the SF-12v2 PF, RP, BP, GH and PCS scores of
HD patients were lower than the corresponding general
population. It was unexpected to find that the SF-12v2
MH and MCS scores of HD patients were significantly
higher than the corresponding general population. The
results of Tukey’s HSD test showed that HBHD patients
had poorer SF-12v2 PF, BP and PCS scores than the age-
sex adjusted general population as well as the CBHD
group. All the Cronbach’s alpha coefficients (Overall HD
patients: 0.812; Age-sex adjusted Hong Kong general
population: 0.842; CBHD patients: 0.823; HBHD patients:
0.809) of SF-12v2 domain scores exceeded the threshold
of 0.7, implying the acceptable internal consistency reli-
ability of the SF-12v2 scale.Factors associated with HRQOL of ESRD patients
receiving HD
Table 3 and Table 4 shows the factors associated with
the domains of HRQOL, PCS and MCS scores using
multiple linear regressions. CBHD patients had signifi-
cantly higher scores in the SF-12v2 PF, BP, GH, RE and
PCS scores than the HBHD patients. Being male was as-
sociated with higher SF-12 v2 PF, BP, RE and PCS scores.
Being employed was associated with higher SF-12 v2 PF,
RP, GH, VT, SF, RE and PCS scores. Smoking was associ-
ated with lower SF-12 v2 PCS but higher MCS scores.
Compared with patients who went to HD sessions alone,
those who were accompanied by others had poorer
SF-12 v2 PF score. No factor was associated with the
SF-12 v2 MH score.
Discussion
In relation to the impact of HD on HRQOL as measured
by the SF-12v2, our HD patients had poorer HRQOL in
the PF, GH domains and PCS with small to moderate ef-
fect sizes of 0.58 (PF), 0.34 (GH) and 0.41 (PCS) than
the adjusted general population. This finding was con-
sistent with the results of a previous study in which
ESRD patients had poorer HRQOL as measured by the
physical dimension of the Short Form-36 [33]. An
American study also revealed that the SF-36 PF domain
of ESRD patients was substantially lower (39.9) than the
US general population [34]. A systematic review found
that the weighted prevalence of the symptoms of fatigue
and tiredness in ESRD patients was 71 % and 44 % of
ESRD patients who suffered from sleep disturbance [35],
which might have led to impairment in activities of daily
living (RF) and of physical functioning (PF) and poor
general health perception (GH). Moreover, many pa-
tients in Hong Kong are influenced by belief in the the-
ories of traditional Chinese Medicine, in which weak
kidney function is detrimental to overall health (GH).
HD patients also had lower SF-12v2 BP score than the
general population, which might be attributable to the
easy muscle fatigue associated with ESRD.
It was encouraging, although unexpected, that HD pa-
tients had better SF-12v2 MH and MCS scores than the
age-sex matched general population, with small to mod-
erate effect sizes of 0.25 (MH) and 0.5 (MCS). Cross-
sectional studies in western populations reported that
the mental health in HD patients was not different from
that of the general population or from patients who had
received renal transplants [36–40]. A study in the US
suggested that there was minimal negative impact of
ESRD on the MH domain of the SF-36 (5 on a 100-
point scale lower than the general population). Previous
studies found that HD patients with psychological adapta-
tion had greater appreciation of life and better mental
health [41, 42] which might be the explanation for the
Table 1 Socio-demographic and additional information between CBHD and HBHD patients
Factor Total CBHD patients HBHD patients P-value
(n = 244) (n = 110) (n = 134)
Socio-demographic
Sex 0.757
Female 40.2 % 39.1 % 41.0 %
Male 59.8 % 60.9 % 59.0 %
Age (mean ± SD), year 56.6 ± 12.7 57.2 ± 13.0 56.0 ± 12.4 0.463
Educational level 0.696
No formal education 8.6 % 10.0 % 7.5 %
Primary 27.0 % 23.6 % 29.9 %
Secondary 53.7 % 55.5 % 52.2 %
Tertiary 10.7 % 10.9 % 10.4 %
Marital status 0.583
Unmarried 34.6 % 32.7 % 36.1 %
Married 65.4 % 67.3 % 63.9 %
Smoking status 0.152
Non-smoker 95.1 % 97.3 % 93.3 %
Current smoker 4.9 % 2.7 % 6.7 %
Working status 0.011*
Not working 79.1 % 86.4 % 73.1 %
Working 20.9 % 13.6 % 26.9 %
Come alone/Accompanied for HD session 0.494
Alone 83.6 % 81.8 % 85.1 %
Accompanied by others 16.4 % 18.2 % 14.9 %
Transportation to dialysis center 0.024*
Walk 8.2 % 8.2 % 8.2 %
Public transport 74.6 % 81.8 % 68.7 %
Taxi/ others 17.2 % 10.0 % 23.1 %
Clinical and Co-morbidity information
Kt/V 0.337
Targeta not achieved 26.8 % 29.6 % 23.8 %
Targeta achieved 73.2 % 70.4 % 76.2 %
Blood haemogloblin 0.239
<9 g/dL 22.8 % 19.4 % 26.1 %
≥ 9 g/dL 77.2 % 80.6 % 73.9 %
Co-morbidities
Yes 78.1 % 77.8 % 78.4 % 0.914
No 21.9 % 22.2 % 21.6 %
CBHD: Community-based haemodialysis; HBHD: Hospital-based haemodialysis; HD: Haemodialysis
*Significant with p-value < 0.05 by chi-square test or t-test as appropriate
aTarget: Kt/V ≥ 1.8 for 2 HD sessions per week or Kt/V ≥ 1.2 for 3 HD sessions per week or Kt/V ≥ 3.6 for weekly data
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our Chinese HD patients. As HD patients need to attend
HD 2 or 3 times a week for several hours each time, there
may be opportunity for the nursing staff to build up rap-
port, enhance knowledge, enable coping and provide morepsychological support to HD patients that are beneficial to
mental health. Another possible explanation may be found
in the “response shift theory” [43]. ESRD patients might
reframe their expectation, and their conceptualization of
health-related quality of life over the course of the disease
Table 2 HRQOL scores of CBHD, HBHD patients and age-sex adjusted HK general population
SF-12v2 Overall HD patientsa (n = 233) Age-sex adjusted HK general
populationa (n = 233)
P-value Effect sizeb CBHD patients (n = 110) HBHD patients (n = 134) P-value for ANOVA Significant
difference***
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Physical functioning 66.85 (32.55) 83.91 (26.03) <0.001* 0.58 73.64 (29.68) 61.38 (34.09) <0.001** 3 > 1 > 2
Role physical 71.35 (31.01) 79.08 (26.07) 0.004* 0.27 71.48 (32.27) 71.36 (30.11) 0.015** 3 > 2
Bodily pain 70.71 (31.62) 78.54 (25.97) 0.004* 0.27 77.50 (32.12) 64.93 (30.21) <0.001** 1, 3 > 2
General health 37.55 (25.78) 46.93 (29.82) <0.001* 0.34 41.36 (24.99) 35.00 (26.51) <0.001** 3 > 2
Vitality 57.40 (24.15) 61.91 (29.09) 0.070 0.17 55.68 (24.10) 58.96 (24.02) 0.123
Social functioning 77.25 (29.69) 81.97 (24.94) 0.064 0.17 78.18 (31.42) 77.43 (28.08) 0.242
Role emotional 78.54 (25.42) 77.25 (23.01) 0.567 0.05 81.36 (25.10) 76.40 (24.94) 0.228
Mental health 75.00 (19.97) 70.06 (18.92) 0.006* 0.25 75.34 (21.11) 74.81 (19.08) 0.020**
Physical component
summary score
42.77 (11.11) 47.50 (11.82) <0.001* 0.41 45.71 (11.02) 40.26 (10.89) <0.001** 1, 3 > 2
Mental component summary
score
54.68 (9.14) 49.82 (10.41) <0.001* 0.50 55.51 (7.96) 54.15 (9.94) <0.001** 1, 2 > 3
HRQOL: Health-related Quality of Life; CBHD: Community-Based Haemodialysis; HBHD: Hospital-Based Haemodialysis; HK: Hong Kong
aOf 2,831 respondents in the study of population norm of the SF-12v2 in Hong Kong, 233 HD patients were matched to 233 general population subjects with sex and exact age. 11 subjects could not be matched
bCohen’s d effect size between HD patients (overall) and HK general population
*Significant difference between HD patients (overall) and HK general population (P < 0.05)
**Significant difference between three groups (P < 0.05) by one-way ANOVA: Group 1, CBHD; Group 2, HBHD; Group 3, Hong Kong general population
***Significant difference between groups by post hoc Tukey’s HSD test (P < 0.05)
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Table 3 Factors associated with SF-12v2 at baseline by multiple linear regressions
PF RP BP GH VT
Independent variables Coef. 95 % CI P-value Coef. 95 % CI P-value Coef. 95 % CI P-value Coef. 95 % CI P-value Coef. 95 % CI P-value
Socio-demographics
Male (vs. Female) 16.22 (7.26,25.17) < 0.001* 8.00 (-1.98,17.98) 0.116 14.85 (4.91,24.79) 0.004* 3.30 (-4.71,11.32) 0.417 1.78 (-6.01,9.57) 0.653
Age 0.09 (-0.28,0.46) 0.624 0.05 (-0.37,0.46) 0.819 −0.07 (-0.48,0.35) 0.750 −0.08 (-0.41,0.25) 0.641 0.27 (-0.06,0.59) 0.105
Educational level
(No formal education)
Primary 2.66 (-14.07,19.38) 0.755 6.94 (-11.70,25.59) 0.464 −9.33 (-27.90,9.24) 0.323 8.47 (-6.51,23.44) 0.266 −1.23 (-15.79,13.32) 0.867
Secondary −2.32 (-18.91,14.28) 0.783 −5.00 (-23.49,13.50) 0.595 −8.30 (-26.72,10.13) 0.375 1.76 (-13.09,16.62) 0.815 −3.50 (-17.93,10.94) 0.633
Tertiary 5.20 (-15.05,25.44) 0.613 −5.26 (-27.83,17.31) 0.646 −3.39 (-25.87,19.09) 0.766 −2.78 (-20.91,15.35) 0.763 −0.74 (-18.36,16.88) 0.934
Married (vs. Unmarried) 0.51 (-8.17,9.19) 0.908 4.57 (-5.10,14.25) 0.353 −3.47 (-13.11,6.17) 0.479 7.37 (-0.40,15.14) 0.063 2.91 (-4.65,10.46) 0.449
Smoker (vs. Non-smoker) −12.80 (-31.27,5.66) 0.173 −3.70 (-24.29,16.88) 0.723 −7.79 (-28.29,12.72) 0.455 −4.50 (-21.03,12.03) 0.592 −1.99 (-18.06,14.08) 0.807
Working (vs. Not working) 17.49 (6.77,28.21) 0.002* 16.42 (4.47,28.37) 0.007* 3.54 (-8.36,15.44) 0.558 12.14 (2.54,21.73) 0.013* 11.84 (2.51,21.17) 0.013*
CBHD, Yes (vs. No) 11.31 (3.22,19.40) 0.006* 2.73 (-6.28,11.75) 0.551 12.33 (3.35,21.31) 0.007* 7.59 (0.35,14.83) 0.040* −2.52 (-9.55,4.52) 0.481
Come alone/ accompanied
for HD session, Accompanied
by others (vs. Alone)
−21.26 (-33.76,-8.76) 0.001* −2.16 (-16.09,11.78) 0.760 7.84 (-6.04,21.72) 0.267 −2.64 (-13.83,8.55) 0.642 −4.27 (-15.15,6.61) 0.440
Transportation to dialysis
center (vs. Walk)
Public transport −3.18 (-18.10,11.74) 0.675 −2.34 (-18.97,14.29) 0.782 12.09 (-4.48,28.66) 0.152 −6.73 (-20.08,6.63) 0.322 −0.43 (-13.41,12.56) 0.949
Taxi/ others −4.75 (-22.20,12.71) 0.592 −3.25 (-22.71,16.21) 0.742 10.26 (-9.12,29.64) 0.298 −10.22 (-25.85,5.41) 0.199 2.63 (-12.56,17.82) 0.733
Clinical and Co-morbidity
information
Kt/V,Targeta achieved
(vs. Targeta not achieved)
−6.85 (-15.72,2.02) 0.129 1.11 (-8.77,10.99) 0.825 −1.37 (-11.22,8.47) 0.784 0.83 (-7.10,8.77) 0.836 −0.72 (-8.44,6.99) 0.854
Blood haemogloblin, ≥ 9 g/dL
(vs. < 9 g/dL)
−0.91 (-10.34,8.51) 0.848 1.17 (-9.34,11.68) 0.826 −3.24 (-13.71,7.23) 0.542 −3.69 (-12.13,4.75) 0.390 1.01 (-7.19,9.22) 0.808
Comorbidities, Yes (vs. No) −5.05 (-14.65,4.55) 0.301 −3.80 (-14.50,6.90) 0.485 4.06 (-6.60,14.72) 0.454 1.38 (-7.21,9.97) 0.752 −3.77 (-12.12,4.58) 0.375
Constant 60.62 (27.13,94.11) < 0.001* 61.42 (24.09,98.75) 0.001* 56.80 (19.62,93.99) 0.003* 34.70 (4.72,64.68) 0.024* 43.54 (14.41,72.68) 0.004*
CBHD: Community-Based Haemodialysis; HD: Haemodialysis; PF: Physical Functioning; RP: Role Physical; BP: Bodily Pain; GH: General Health; VT: Vitality; CI: Confidence Interval
*Significant with p-value < 0.05
aTarget: Kt/V ≥ 1.8 for 2 HD sessions per week or Kt/V ≥ 1.2 for 3 HD sessions per week or Kt/V ≥ 3.6 for weekly data
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Table 4 Factors associated with SF-12v2 at baseline by multiple linear regressions
SF RE MH PCS MCS
Independent variables Coef. 95 % CI P-value Coef. 95 % CI P-value Coef. 95 % CI P-value Coef. 95 % CI P-value Coef. 95 % CI P-value
Socio-demographics
Male (vs. Female) 4.70 (-4.69,14.08) 0.325 9.93 (2.00,17.85) 0.014* −1.48 (-7.94,4.97) 0.651 7.55 (4.40,10.70) < 0.001* −0.17 (-3.06,2.73) 0.910
Age −0.11 (-0.50,0.28) 0.587 −0.11 (-0.44,0.22) 0.508 −0.09 (-0.35,0.18) 0.527 −0.04 (-0.17,0.09) 0.517 −0.07 (-0.19,0.05) 0.240
Educational level
(No fomal education)
Primary 0.17 (-17.37,17.70) 0.985 −4.67 (-19.48,10.13) 0.534 3.84 (-8.22,15.89) 0.531 −0.63 (-6.52,5.25) 0.832 0.77 (-4.63,6.18) 0.778
Secondary −8.66 (-26.05,8.74) 0.328 −12.90 (-27.59,1.78) 0.085 2.69 (-9.27,14.65) 0.658 −1.82 (-7.66,4.02) 0.539 −2.03 (-7.40,3.33) 0.455
Tertiary −5.60 (-26.83,15.63) 0.603 −6.50 (-24.42,11.43) 0.475 6.28 (-8.32,20.87) 0.397 −2.46 (-9.59,4.66) 0.496 1.18 (-5.37,7.72) 0.724
Married (vs. Unmarried) 1.47 (-7.63,10.57) 0.751 2.25 (-5.44,9.93) 0.565 −1.71 (-7.97,4.54) 0.590 1.87 (-1.19,4.92) 0.229 1.34 (-1.46,4.15) 0.347
Smoker (vs. Non-smoker) 15.42 (-3.95,34.78) 0.118 4.72 (-11.62,21.07) 0.569 10.22 (-3.09,23.53) 0.132 −7.27 (-13.76,-0.77) 0.029* 6.64 (0.67,12.62) 0.029*
Working (vs. Not working) 11.30 (0.06,22.54) 0.049* 11.17 (1.68,20.66) 0.021* 1.84 (-5.88,9.57) 0.638 4.60 (0.83,8.37) 0.017* 2.15 (-1.32,5.61) 0.223
CBHD, Yes (vs. No) 2.71 (-5.77,11.19) 0.530 8.54 (1.39,15.70) 0.020* 1.62 (-4.21,7.44) 0.585 4.77 (1.93,7.62) 0.001* 2.46 (-0.15,5.08) 0.065
Come alone/ accompanied for
HD session, Accompanied by
others (vs. Alone)
−5.64 (-18.74,7.47) 0.397 −1.79 (-12.85,9.28) 0.750 −2.89 (-11.90,6.12) 0.528 −3.34 (-7.74,1.05) 0.135 0.98 (-3.06,5.02) 0.633
Transportation to dialysis
center (vs. Walk)
Public transport −13.18 (-28.82,2.47) 0.098 3.50 (-9.71,16.71) 0.602 −2.30 (-13.06,8.46) 0.674 0.66 (-4.59,5.91) 0.804 −0.21 (-5.03,4.61) 0.931
Taxi/ others −11.47 (-29.77,6.83) 0.218 8.25 (-7.20,23.70) 0.294 −2.80 (-15.38,9.79) 0.661 −1.39 (-7.53,4.75) 0.655 0.09 (-5.56,5.73) 0.976
Clinical and Co-morbidity
information
Kt/V,Targeta achieved
(vs. Targeta not achieved)
−3.77 (-13.06,5.53) 0.425 1.18 (-6.67,9.02) 0.768 −4.33 (-10.72,2.06) 0.183 −0.42 (-3.54,2.69) 0.789 −0.43 (-3.30,2.43) 0.766
Blood haemogloblin, ≥ 9 g/dL
(vs. < 9 g/dL)
−5.06 (-14.94,4.83) 0.314 −2.74 (-11.08,5.61) 0.518 −0.80 (-7.60,5.99) 0.816 0.86 (-2.46,4.18) 0.609 −0.09 (-3.14,2.96) 0.954
Comorbidities, Yes (vs. No) 2.32 (-7.74,12.39) 0.649 −3.51 (-12.00,4.99) 0.416 −0.15 (-7.07,6.77) 0.965 −0.30 (-3.68,3.07) 0.860 1.91 (-1.19,5.02) 0.225
Constant 98.58 (63.47,133.69) < 0.001* 79.74 (50.10,109.39) < 0.001* 83.43 (59.29,107.57) < 0.001* 38.35 (26.57,50.13) < 0.001* 55.58 (44.75,66.41) < 0.001*
CBHD: Community-Based Haemodialysis; HD: Haemodialysis; SF: Social Functioning; RE: Role Emotional; MH: Mental Health; PCS: Physical Component Summary; MCS: Mental Component Summary; CI:
Confidence Interval
*Significant with p-value < 0.05
aTarget: Kt/V ≥ 1.8 for 2 HD sessions per week or Kt/V ≥ 1.2 for 3 HD sessions per week or Kt/V ≥ 3.6 for weekly data
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scores than the general population. Further qualitative
studies would be useful to explore the illness experience,
coping and mental health of ESRD and HD patients.
Of interest, both mental or physical health-related
summary scores of our Chinese HD patients in Hong
Kong were higher than those of HD patients in other
countries including Singapore [13], Japan [44], Brazil
[45], Europe [44], the United Kingdom [46] and the US
[44, 47, 48]. Our patients also had better physical and
mental component summary of HRQOL (PCS: 42.8;
MCS: 54.7) than others of the same ethnicity, namely
HD patients in mainland China (PCS: 36.2; MCS: 43.8)
and Taiwan (PCS: 36.3; MCS: 37.5) [49, 50]. The results
revealed that the perceived life impact of disease is
culture-specific but is also influenced by health beliefs as
well as the country’s health care system. Health care
financing may also influence HRQOL especially for
people with serious chronic diseases that require expen-
sive life-saving treatments such as HD [44]. For example,
HD patients in the US had better SF-36 MCS than those
in Japan and Europe, but HD patients in Japan had better
SF-36 PCS of than those in the US and Europe [44]. Inter-
pretation of HRQOL findings must take into consideration
the cultural and health care context of the population.
Compared with patients undergoing CBHD, those
patients undergoing HBHD had poorer SF-12v2 PCS, PF
and BP scores, but no significant difference in the
SF-12v2 MCS or other domain scores, by ANOVA and
after adjustment of confounders by multiple regressions.
This was different from the findings in the literature
which showed no difference between groups in both
physical and mental components [51]. This may be due
to the “self-selection” of more physically fit patients for
CBHD. Although the socio-demographics and propor-
tion of presence of co-morbidities of the two groups
were statistically similar, the severity level of comorbidi-
ties in HBHD group may be higher than that in CBHD
because of the requirement that patients be independent
and ambulatory for the CBHD group. More detailed ex-
ploration for any difference in the health status of the
HBHD and CBHD patients on entry into programme
and a longitudinal study on the change in HRQOL of
both groups would provide insight into whether HD set-
ting has an independent effect on HRQOL. On the other
hand, there were some patients in the hospital, who met
the referral criteria, but refused to transfer to the com-
munity centre because they were worried about transfer-
ring to an unfamiliar environment.
The results of socio-demographic factors associated
with the HRQOL of HD patients showed that male
HD patients had better scores in physical domains of
HRQOL but no difference in mental domains compared
with female patients. Numerous studies had reportedpoorer HRQOL in several or all dimensions in female
compared with male dialysis patients [50, 52–54]. The
finding that females have poorer HRQOL is consistent
with that found in the general populations [50].
We found that employed HD patients had better
SF-12v2 scores in several HRQOL domains including PF,
RP, GH, VT, SF, RE as well as the PCS which is consist-
ent with findings cited in the literature [33, 50, 55, 56].
Patients are less likely to perceive impairment in their
activities of daily living when they are able to continue
active employment, but the low employment rate is
notable in our HD population. Other studies found that
the need to frequently attend HD sessions or disability
discrimination [57, 58] to be reasons for the low em-
ployment rate. Nonetheless, counselling and vocational
rehabilitation should be provided to encourage dialysis
patients who are able to work to do so, even on a volun-
tary basis, for enhancement of HRQOL.
It is well known that smoking is a risk factor for
increasing disease burden [59] which may explain the
inverse relationship observed between smoking and
SF-12v2 PCS, but paradoxically a direct relationship was
found between smoking and SF-12v2 MCS. The benefit
to mental health from smoking may be from the pleas-
ure or relaxation derived from the habit [60], though this
is inconclusive due to the cross-sectional design and
small proportion of smokers in our study (<5 %).
HD patients who came to HD centre accompanied by
others had much lower HRQOL in PF than those who
attended alone. This is expected, as patients with poorer
physical functioning were might not have been able to
attend HD session alone and the accompanying person
was usually a domestic helper whose responsibility was
to physically assist the patient to and from the HD ses-
sion. Conversely, patients who were physically fit should
have had no problem to attend HD session alone.
We found that clinical measures and the presence of
co-morbidities were not associated with HRQOL of HD
patients. Although dialysis adequacy and anaemia are
key dialysis outcome measures and predictors of morbidity
and mortality [61–63], they were not associated with pa-
tients’ HRQOL. Similarly the presence of co-morbidities
was not associated with HRQOL. Some studies observed
that there was a positive correlation between haemoglobin
level and perceived HRQOL [64–66] and a negative cor-
rection between co-morbidity and HRQOL [50, 67–69].
However, other reports were consistent with our results,
showing that the Kt/V and haemoglobin did not signifi-
cantly correlate with HRQOL of dialysis patients [70, 71].
Strengths and limitations of this study
There were two main strengths of the present study. First,
we were able to determine the impact of ESRD and HD
on HRQOL through normative comparisons of HRQOL
Wan et al. Health and Quality of Life Outcomes  (2015) 13:108 Page 10 of 12between our patients and age-sex matched subjects from
the general population. Second, HD patients were recruited
in both hospital and community settings which permitted
the exploration of possible HRQOL differences between
patients undergoing dialysis in contrasting settings.
There were a number of limitations to this study.
Firstly, all subjects were recruited from the community
centres and government-based hospitals, and the results
may not be generalizable to ESRD patients undergoing
dialysis in the private settings. Second, the HRQOL was
measured by the SF-12v2. As a generic measure, the
SF-12v2 might not be sufficiently sensitive as disease-
specific measures to detect differences between HD pa-
tient groups. For example, the finding that no factor was
associated with mental health domain of the SF-12v2, or
the lack of association between clinical parameters and
HRQOL scores might be due to the insensitivity of the
measure. Further study with the dual use of generic and
disease-specific measures may help evaluate HRQOL
of HD patients more comprehensively. Third, additional
clinical parameters such as albumin, creatinine and cal-
cium would help to obtain a more complete picture of
which dialysis outcome measures relate to HRQOL of
HD patients. Fourth, it would have been be worthwhile
to investigate the difference in HRQOL between two-times
and three-times weekly HD, had the data been available.
Lastly, as a cross-sectional study, only preliminary informa-
tion about association of HRQOL and risk factors was pos-
sible to be obtained and longitudinal studies are needed to
evaluate any causal relationship as well as the change of
HRQOL among HD patients in different settings.
Conclusions
Different from most other previous studies, our study
demonstrated HD patients as having better mental
health-related quality of life when compared to the gen-
eral population. CBHD patients seemed to perceive bet-
ter HRQOL in physical domains but were no different in
mental domain scores from HBHD. Factors associated
with poorer HRQOL included female gender, smoking,
and not working. Features of the HD setting as well as
other modifiable factors should be further investigated
to improve HRQOL for HD patients. Longitudinal stud-
ies would help establish causation and evaluate changes
in HRQOL over time.
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